Contact: Ralph Barry, Chief Business Officer, Aegis Therapeutics LLC
1-858-618-1400 Ext. 102, Email: rbarry@aegisthera.com

Yearly Archives: 2005

Aegis Therapeutics’ Intravail® Drug Delivery Technology Gaining Acceptance

San Diego, CA – August 1, 2005 – Aegis Therapeutics today announced that it has entered into a licensing agreement for its patented Intravail™ drug delivery technology for application to several undisclosed pediatric therapeutics being developed by an unnamed partner. In June 2005, Aegis announced the expansion of its earlier licensing agreement with Intranasal Technologies […]

Aegis Therapeutics Files First Drug Master File with the FDA

SAN DIEGO, CA August 8, 2005 / BusinessWire /– Aegis Therapeutics LLC today announced that it has filed its first Drug Master File (DMF) for Intravail™ with the U.S. Food and Drug Administration (FDA) as part of its goal of broadly enabling intranasal delivery of peptide and protein drugs across a wide spectrum of disease […]

Aegis Therapeutics Files First Drug Master File with the FDA

SAN DIEGO, CA August 8, 2005 / BusinessWire /– Aegis Therapeutics LLC today announced that it has filed its first Drug Master File (DMF) for Intravail™ with the U.S. Food and Drug Administration (FDA) as part of its goal of broadly enabling intranasal delivery of peptide and protein drugs across a wide spectrum of disease […]

Aegis Therapeutics’ Intravail® Drug Delivery Technology Gaining Acceptance

San Diego, CA – August 1, 2005 – Aegis Therapeutics today announced that it has entered into a licensing agreement for its patented Intravail™ drug delivery technology for application to several undisclosed pediatric therapeutics being developed by an unnamed partner. In June 2005, Aegis announced the expansion of its earlier licensing agreement with Intranasal Technologies […]

Aegis Therapeutics Invited to Participate in 2006 Gordon Research Conference on Peptides

SAN DIEGO, CA July 5, 2005/BusinessWire/– Aegis Therapeutics, a leader in intranasal and transmucosal delivery of peptide, protein and non-protein macromolecular drugs, today announced that Edward T. Maggio, Ph.D., President and Chief Executive Officer, will present research data on Aegis’ patented Intravail™ intranasal and transmucosal drug delivery technology at the Drug Delivery session of the […]

Aegis Therapeutics Initiates Feasibility Studies for Intranasal Drug Delivery in Type 2 Diabetes and a Second Undisclosed Metabolic Disease

San Diego, CA  June 6, 2005 — Aegis Therapeutics announced that the Company has entered into separate agreements with two undisclosed research partners to evaluate the application of its patented Intravail™ technology for development of proprietary formulations for the nasal delivery of compounds useful for the treatment of type 2 diabetes and a second undisclosed […]

Aegis Therapeutics and Albany Medical College Combine Discoveries to Create a Novel Anti-Obesity Nasal Spray

SAN DIEGO, CA May 16, 2005 – Aegis Therapeutics officials and Albany Medical College researchers announced today that they have entered into a license agreement relating to the Albany Medical College’s patented anti-obesity peptide.  Aegis plans to employ its patented Intravail™ intranasal peptide delivery technology with the Albany Medical College’s anti-obesity peptide to assess its […]

Intranasal Technology, Inc. Licenses Aegis Therapeutics’ Intravail™ Drug Delivery Technology

San Diego, CA and Lexington, KY – April 13, 2005 – Aegis Therapeutics (“Aegis”) and Intranasal Technology, Inc. (“ITI”) today announced that they have entered into a collaborative agreement to apply Aegis’ patented Intravail™ drug delivery technology to a therapeutic to be developed by ITI. “ITI has an impressive product pipeline and unique manufacturing process […]